Some of the biggest VC firms are backing both OpenAI and Anthropic; the growing trend of backing rival startups, once taboo, shows how AI has scrambled funding
Silicon Valley investors are breaking a longstanding taboo by investing in competing startups.
Context & Ripple Effects
This marks a break from the portfolio-conflict norms that traditionally kept major venture firms from financing direct rivals. It follows an earlier AI-oriented shift in which Sequoia India’s new investments became predominantly AI-focused, making broad exposure to the sector increasingly important to generalist investors.
Subsequent coverage underscores why the overlap matters: OpenAI and Anthropic together accounted for a large share of reported global VC funding in the first half of 2026, a concentration of capital in the two frontier labs that makes sitting out either company harder for major funds.
First-order effects
- Large VC firms can retain economic exposure to both leading AI labs rather than making a single winner-take-all portfolio bet.
- OpenAI and Anthropic gain access to a deeper, overlapping investor pool, while those investors must manage sharper confidentiality and conflict-of-interest boundaries.
Second-order effects
- Other AI startups seeking capital may face more investor diligence around information rights, board roles, and whether a fund already backs a close competitor.
- The move reinforces capital’s pull toward the best-funded labs; the reported funding concentration around OpenAI and Anthropic can leave less investor attention for firms outside that narrow frontier race.
Third-order effects
- If dual backing becomes normalized, venture portfolios may increasingly treat frontier AI as a concentrated sector exposure rather than a set of mutually exclusive company bets.
- That shift could make governance around shared investors a more important competitive variable, particularly where portfolio companies compete for the same customers, talent, or infrastructure.
The trend: Frontier-AI investing is shifting from exclusive company selection toward diversified exposure to a small set of capital-intensive labs.